Login to Your Account



Belinostat Data Analysis Sends TopoTarget's Shares Climbing

By Cormac Sheridan
Staff Writer

Wednesday, August 29, 2012
Shares of TopoTarget A/S gained 10 percent Tuesday following an additional analysis of data from a Phase II trial of belinostat in 89 patients with cancer of unknown primary (CUP) origin, which raises hopes that the drug, a histone deacetylase inhibitor, could have potential in solid tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription